ALXN:NSD-Alexion Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 102.80

Change

+1.30 (+1.28)%

Market Cap

USD 22.70B

Volume

2.13M

Average Target Price

USD 140.32 (+36.49%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830, which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases, as well as with Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc. to advance the development of CAEL-101 for light chain amyloidosis; agreement with Stealth BioTherapeutics Corp. to co-develop and commercialize therapy for mitochondrial diseases; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-18.46 (-6.48%)

USD73.88B 49.39 37.03
REGN Regeneron Pharmaceuticals, Inc

-24.70 (-4.33%)

USD64.13B 28.64 21.76
SGEN Seattle Genetics, Inc

-4.04 (-2.59%)

USD26.26B N/A N/A
INCY Incyte Corporation

-0.69 (-0.69%)

USD21.60B 47.64 35.20
MRNA Moderna, Inc

-11.29 (-16.36%)

USD21.42B N/A N/A
GMAB Genmab A/S

+1.22 (+4.16%)

USD19.59B 52.40 5.57
BMRN BioMarin Pharmaceutical Inc

+6.23 (+6.39%)

USD17.63B 154.78 92.86
ALNY Alnylam Pharmaceuticals, Inc

-4.09 (-2.91%)

USD16.13B N/A N/A
GLPG Galapagos NV

+4.45 (+2.22%)

USD13.13B 70.13 37.04
BGNE BeiGene, Ltd

+4.78 (+3.00%)

USD12.41B N/A N/A

ETFs Containing ALXN

Symbol Name Weight Mer Price(Change) Market Cap
PBE Invesco Dynamic Biotechno.. 4.78 % 0.57 %

-1.17 (-1.99%)

USD0.22B
BBH VanEck Vectors Biotech ET.. 4.32 % 0.35 %

-4.28 (-2.71%)

USD0.40B
BIS ProShares UltraShort Nasd.. 3.02 % 0.95 %

+0.33 (+3.82%)

USD0.01B
ZBIO ProShares UltraPro Short .. 3.02 % 0.95 %

N/A

USD2.51M
BTEE:LSE iShares Nasdaq US Biotech.. 2.70 % 0.35 %

+0.03 (+0.51%)

USD0.10B
BTEK:LSE iShares Nasdaq US Biotech.. 2.70 % 0.35 %

-0.05 (-0.92%)

USD0.10B
BTEC:LSE iShares Nasdaq US Biotech.. 2.68 % 0.35 %

+0.02 (+0.40%)

USD0.07B
IBB iShares Nasdaq Biotechnol.. 2.48 % 0.47 %

-2.53 (-1.90%)

USD7.94B
ZUH:CA BMO Equal Weight US Healt.. 1.97 % 0.35 %

-0.54 (-0.88%)

USD0.35B
ZHU:CA BMO Equal Weight US Healt.. 1.87 % 0.35 %

-0.42 (-1.12%)

USD0.01B
LABD Direxion Daily S&P Biotec.. 1.76 % 1.06 %

+0.31 (+7.06%)

USD0.08B
JKG iShares Morningstar Mid-C.. 1.22 % 0.25 %

+5.92 (+3.41%)

USD0.57B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.12 (-2.12%)

N/A
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.04 %

-3.73 (-7.15%)

USD0.38B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-2.83 (-4.07%)

USD0.15B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.95% 46% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.95% 45% F 63% D
Trailing 12 Months  
Capital Gain -19.15% 38% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.15% 38% F 41% F
Trailing 5 Years  
Capital Gain -38.85% 54% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.85% 53% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain -9.06% 43% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.06% 42% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 15.04% 97% A+ 79% C+
Risk Adjusted Return -60.24% 26% F 13% F
Market Capitalization 22.70B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.81 45% F 68% D+
Price/Book Ratio 1.95 79% C+ 49% F
Price / Cash Flow Ratio 10.89 7% F 25% F
EV/EBITDA 8.43 27% F 64% D
Management Effectiveness  
Return on Equity 22.13% 97% A+ 91% A-
Return on Invested Capital 18.35% 93% A 91% A-
Return on Assets 9.26% 97% A+ 94% A
Debt to Equity Ratio 21.07% 53% F 65% D
Technical Ratios  
Short Ratio 2.01 64% D 56% F
Short Percent 2.28% 71% C- 58% F
Beta 1.41 55% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.